联系方式
邮箱：shiming@hit.edu.cn
个人简介
2000-2004年：哈尔滨师范大学 生物技术学士
2005-2007年：哈尔滨工业大学 生物化学与分子生物学硕士
2007-2014年：哈药集团生物工程有限公司/哈药集团技术中心工程师
2009-2014年：哈尔滨工业大学 生物医学工程博士
2011-2012年：美国德州A&M大学联合培养博士
2014-2017年：哈尔滨工业大学 生命科学与技术学院讲师
2019-2020年：哈佛大学 医学院访问学者
2018-至今：哈尔滨工业大学 生命科学与技术学院副教授
Personal Profile
2000-2004, B.S., Biotechnology, Harbin Normal University, China
2005-2007, M.S., Biochemistry and molecular biology, Harbin Institute of Technology, China
2007-2014, Engineer, Harbin pharmaceutical group bioengineering company, Harbin
2009-2014, Ph.D., Biomedical engineering, Harbin Institute of Technology, China
2011-2012, joint Ph.D., IBT - Texas A&M Health Science Center, Houston, TX, USA
2014-2017, Lecturer, Harbin Institute of Technology, Harbin
2019-2020, Visiting Associate Professor/Research Associate, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School; Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston
2018-Now, Associate professor, Harbin Institute of Technology, Harbin
研究方向和领域
肿瘤细胞生物学与肿瘤免疫学研究方向
1.肿瘤发生的分子机制
2.肿瘤免疫和肿瘤微环境
Research Area
Cancer cell biology and Cancer immunology
1. Molecular mechanism of tumorigenesis
2. Cancer immunology and cancer microenvironment
研究内容
1. 从事肿瘤相关基因的生物学功能研究，已发现MARVELD1基因在肿瘤细胞中表观沉默的分子机制及临床意义（Mol Carcinog, 2016&2019）；以及GAP43基因在结肠癌中的生物学作用(BMC cancer 2021）；
2. 在天然免疫模式识别受体PGLYRP2介导抗肿瘤天然免疫应答的研究中，发现PGLYRP2基因的表达与肿瘤微环境、肿瘤浸润淋巴细胞之间的关系，明确了PGLYRP2蛋白对肝癌免疫应答的调控功能与具体机制（Hepatology, 2020），以及PGLYRP2蛋白作为肿瘤免疫标志物的潜在应用价值（国家发明专利，2019）。
Research Interests
1. Study the function of cancer-associated genes in tumorigenesis, and have found the role of MARVELD1 and GAP43 in cancer development (Mol Carcinog, 2016&2019; BMC cancer 2021).
2. Study the function of PGLYRP2 in cancer immunology, and have found the role of PGLYRP2 in regulating cancer immune microenvironment (Hepatology, 2020). PGLYRP2 acts as potential biomarker for adequate immune responses against cancer (patient 2019).
研究成果
1. Chen X#, Wu H#, Feng J#, Li Y, Lv J, Shi W, Fan W, Xiao L, Sun D, Jiang M*,Shi M*. Transcriptome profiling unveils GAP43 regulates ABC transporters and EIF2 signaling in colorectal cancer cells. BMC Cancer. 2021 Jan 5;21(1):24.
2. Yang Z#, Feng J#, Xiao L#, Chen X, Yao Y, Li Y, Tang Y, Zhang S, Lu M, Qian Y, Wu H*,Shi M*. Tumor-Derived Peptidoglycan Recognition Protein 2 Predicts Survival and Antitumor Immune Responses in Hepatocellular Carcinoma. Hepatology. 2020 May;71(5):1626-1642.
3.Shi M#,*, Zhang P#, Vora SM, Wu H*. Higher-order assemblies in innate immune and inflammatory signaling: A general principle in cell biology. Curr Opin Cell Biol. 2020 Apr;63:194-203.
4. Zhang C#, Han F#,Shi M#, Sun H, Li Y, Ci Y, Yao Y, Dou P, Akhtar ML, Nie H, He J, Li Y*. MARVELD1 interacting with catalase regulates reactive oxygen species metabolism and mediates the sensitivity to chemotherapeutic drugs in epithelial tumors of the reproductive system.Mol Carcinog. 2019 Aug;58(8):1410-1426.
5. Li K, Qu S, Chen X, Wu Q,Shi M*. Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways. Int J Mol Sci. 2017 Feb 14;18(2).
6.Shi M, Chen X, Ye K, Yao Y, Li Y*. Application potential of toll-like receptors in cancer immunotherapy: Systematic review. Medicine (Baltimore). 2016 Jun;95(25):e3951.
7.Shi M, Zhang Y, Liu L, Zhang T, Han F, Wang F, McKeehan L. Wallace, Li Y*, Zhang D*. MAP1S controls bacterial phagocytosis through TLR signaling. J Biol. Chem. 2016 Jan 15;291(3):1243-50.
8. Yao Y#,Shi M#, Liu S, Li Y, Guo K, Ci Y, Liu W, Li Y*. MARVELD1 modulates cell surface morphology and suppresses epithelial-mesenchymal transition in non-small cell lung cancer. Mol Carcinog. 2016 Nov;55(11):1714-1727.
9.Shi M, Wang S, Yao Y, Li Y, Zhang H, Han F, Nie H, Su J, Wang Z, Yue L, Cao J, Li Y*. Biological and clinical significance of epigenetic silencing of MARVELD1 gene in lung cancer. Sci Rep. 18(4):7545, 2014.
10.Shi M, Yao Y, Han F, Li Y*. MAP1S Controls Breast Cancer Cell TLR5 Signaling Pathway and Promotes TLR5 Signaling-based Tumor Suppression. PloS One. 9(1):e86839, 2014.
11.Shi M, Yao Y, Li Y*. TLR5 signaling induces autophagic cell death to inhibit breast cancer via novel autophagic adaptor MAP1S. Clinical and Experimental Pharmacoogy and Physiology. 40(1): 03–18, 2013.
12. Wu J, Sun P, Chen Q, Sun Y,Shi M, Mang G, Yu S, Zheng Y, Li Z, Sun M, Fang S, Zhang Y, Tian J, Mingyan E, Zhang M, Yu B. Metabolic reprogramming orchestrates CD4 + T-cell immunological status and restores cardiac dysfunction in autoimmune induced-dilated cardiomyopathy mice. J Mol Cell Cardiol. 2019 Oct;135:134-148.
13. Li Y, Wu Y, Zhang X, Bai Y, Akthar LM, Lu X,Shi M, Zhao J, Jiang Q, Li Y. SCIA: A Novel Gene Set Analysis Applicable to Data With Different Characteristics. Front Genet. 2019 Jun 25;10:598.
14. Zhang H, Hua Y, Jiang Z, Yue J,Shi M, Zhen X, Zhang X, Yang L, Zhou R, Wu S. Cancer-associated Fibroblast-promoted LncRNA DNM3OS Confers Radioresistance by Regulating DNA Damage Response in Esophageal Squamous Cell Carcinoma. Clin Cancer Res. 2019 Mar 15;25(6):1989-2000.
15. Wu J, Zhang H, Zheng Y, Jin X, Liu M, Li S, Zhao Q, Liu X, Wang Y,Shi M, Zhang S, Tian J, Sun Y, Zhang M, Yu B. The Long Noncoding RNA MALAT1 Induces Tolerogenic Dendritic Cells and Regulatory T Cells via miR155/Dendritic Cell-Specific Intercellular Adhesion Molecule-3 Grabbing Nonintegrin/IL10 Axis. Front Immunol. 2018 Aug 13;9:1847.
16. Wang ZY,Shi M, Li Y*. Importin-β1 plays a key role in the nucleocytoplasmic transportation process of MARVELD1. Mol Biol. 49(3):491-7, 2015.
17. Lu X, Nie H, Li Y, Cao Z, Liu X,Shi X, Shi M, Zhang Y, Li Y*. Comprehensive characterization and evaluation of hepatocellular carcinoma by LC–MS based serum metabolomics. Metabolomics. DOI: 10.1007/s11306-015-0797-4, 2015.
18. Wang S, Hu J, Yao Y,Shi M, Yue L, Han F, Zhang H, He J, Liu S, Li Y*. MARVELD1 regulates integrin beta1-mediated cell adhesion and actin organization via inhibiting its pre-mRNA processing. Int J Biochem Cell Biol. 45(11):2679-2687, 2013.
开设的课程
生物物质分离工程
Biomass Separation Engineering
教师个人主页链接
